Melodi Health, a Minneapolis, MN-based medical device company, raised $10.75M in Series A funding.
Backers included HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund, and Three Bridges Private Capital.
The company intends to use the funds to further enhance its clinical activities and additional product development activities.
Led by CEO Sarah Worrell, and chief medical officer, Hunter Moyer, MD, Melodi Health is committed to advancing breast reconstruction through surgical innovation. Its flagship offering, the Melodi Matrix, is a bioabsorbable mesh that elutes antibiotic agents and is fully absorbed by the body.
The company also announced the launch of the “ARIA” investigational device exemption (IDE) trial, a multicenter, nationwide, randomized, controlled study evaluating the safety and efficacy of the Melodi Matrix™ to support an FDA Approval for an indication in breast reconstruction. The Melodi Matrix technology was licensed from Medtronic.
FinSMEs
29/08/2024